Welcome toGeniouskin
About Us
Geniouskin creates a living skin substitute using the patient’s own cells.
Geniouskin
Geniouskin is an advanced autologous skin regeneration platform designed to rebuild living, functional, and naturally pigmented skin.
By combining the three essential skin cell types, keratinocytes, fibroblasts, and melanocytes — into a single therapeutic construct, Geniouskin aims to go beyond simple wound coverage and restore the structure, biology, and appearance of real human skin.
Watch the video learn more
Technology
Two steps. One cure.
The Process
Geniouskin’s Process AI continuously monitors cell culture conditions in real time —analyzing growth patterns, detecting contamination risks, and determining the optimal timing for each production stage — reducing variability and cutting manufacturing costs by an estimated 25–40% at scale.
AI Clinical
Geniouskin’s Clinical AI analyzes wound photography at each follow-up visit to track re-epithelialization progress, predict healing trajectory, and flag early signs of complication —giving clinicians a standardized, data-driven decision support tool that strengthens evidence
generation across every treated patient
From bench to bedside
A clear path forward from research to market launch.
Phase 0 complete
First-In-human
Clinical Validation
(Phase 1 Readout)
Multi-Country Expansion (Multiple Eu Centers)
Pivotal Development (Phase 2 Readout)
Toward Approval (Pivotal Phase 3 Trial Completion)
2035+ -Market Access & Industrialization
(Conditional EMA/FDA Approval Pathway)
Our Team
A highly qualified team combining clinical, scientific, and business expertise.
Professor. Vincent Casoli, MD, PhD, former Head of the Plastic and Reconstructive Surgery Department at CHU de Bordeaux and Professor at the University of Bordeaux, is an expert in complex reconstruction, burns, and microsurgery.
Co-inventor of Geniouskin®️, he bridges reconstructive surgery and regenerative medicine.
Patrick Alexandre is a serial entrepreneur with cross-sector experience across the US and Europe, bringing a proven track record in brand positioning, business development, and stakeholder orchestration.
At Geniouskin, he leads strategic development; from clinical pathway structuring to investor narrative, regulatory partnerships, and market positioning.
Pre-clinical validation complete.
Preclinical, murine model.
patients worldwide with chronic wounds
annual global wound care market
recurrence rate with current treatments
graft take rate in pre-clinical models
